| Ident. | Authors (with country if any) | Title |
|---|
| 000000 (2021) |
Aniruddha Singh [États-Unis] ; Muhammad S. Akbar [États-Unis] ; Doug Mcelroy [États-Unis] ; Matthew Mccurdy [États-Unis] ; Fletcher Young [États-Unis] ; Jayshree Thomas [États-Unis] ; Chrystie Nguyen [États-Unis] ; Kristopher S. Pfirman [États-Unis] | The electrocardiographic manifestations and derangements of 2019 novel coronavirus disease (COVID-19). |
| 000011 (2021) |
Matthieu Million [France] ; Audrey Giraud-Gatineau [France] ; Jean-Christophe Lagier [France] ; Philippe Parola [France] ; Philippe Gautret [France] ; Didier Raoult [France] | Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. |
| 000015 (2021) |
Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique] | Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. |
| 000016 (2021) |
Claudia Lilli ; Annibale Biggeri [Italie] ; Chiara Zingaretti ; Bernadette Vertogen ; Valeria Frassineti ; Roberto Vespignani ; Veruska Grossi ; Caterina Florescu ; Laura Matteucci ; Chiara Pazzi ; Alberto Bongiovanni ; Francesco Limarzi ; Valentina Fausti ; Lucia Bertoni ; Caterina Donati ; Francesca Galardi ; Nicola Gentili ; Francesco Mazza ; Giovanni Martinelli ; Oriana Nanni | Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. |
| 000022 (2021) |
E. Díaz [Espagne] ; R. Amézaga Menéndez [Espagne] ; P. Vidal Cortés [Espagne] ; M G Escapa [Espagne] ; B. Suberviola [Espagne] ; A. Serrano Lázaro [Espagne] ; P. Marcos Neira [Espagne] ; M. Quintana Díaz [Espagne] ; M. Catalán González [Espagne] | [Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. |
| 000026 (2021) |
M. Bovet [Allemagne] ; D. Wadsack [Allemagne] ; F. Kosely [Allemagne] ; W. Zink [Allemagne] ; R. Zahn [Allemagne] | [Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab]. |
| 000027 (2021) |
S. Ortonobes Roig [Espagne] ; N. Soler-Blanco ; I. Torrente Jiménez ; E. Van Den Eynde Otero ; M. Moreno-Ari O ; M. G Mez-Valent | [Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients]. |
| 000028 (2021) |
X S Wang [République populaire de Chine] ; J H Cai [République populaire de Chine] ; M. Zeng [République populaire de Chine] ; H. Tian [République populaire de Chine] ; H L Chang [République populaire de Chine] ; Y L Ge [République populaire de Chine] ; J J Li [République populaire de Chine] ; Z Q Wei [République populaire de Chine] ; J S Wang [République populaire de Chine] | [Clinical analysis of liver chemistries in children and adolescent with 2019-nCoV infection]. |
| 000033 (2021) |
Dania Altulea [Pays-Bas] ; Sjors Maassen [Pays-Bas] ; Maksim V. Baranov [Pays-Bas] ; Geert Van Den Bogaart [Pays-Bas] | What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. |
| 000035 (2021) |
L. Anedda [Italie] ; L. Bianchini ; L. Cuzzolin ; G. Finco ; V. Fanos ; M A Marcialis | What if COVID-19 affects the child: which weapons and how to use them. |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
| 000049 (2021) |
Boghuma K. Titanji [États-Unis] ; Monica M. Farley [États-Unis] ; Ashish Mehta [États-Unis] ; Randi Connor-Schuler [États-Unis] ; Abeer Moanna [États-Unis] ; Sushma K. Cribbs [États-Unis] ; Jesse O'Shea [États-Unis] ; Kathryn Desilva [États-Unis] ; Bonnie Chan [États-Unis] ; Alex Edwards [États-Unis] ; Christina Gavegnano [États-Unis] ; Raymond F. Schinazi [États-Unis] ; Vincent C. Marconi [États-Unis] | Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. |
| 000057 (2021) |
Nobuaki Mori [Japon] ; Mitsuya Katayama [Japon] ; Shigenari Nukaga [Japon] | Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. |
| 000060 (2021) |
Diana Laila Ramatillah [Indonésie] ; Suri Isnaini [Indonésie] | Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. |
| 000063 (2021) |
Jennie H. Best [États-Unis] ; Amanda M. Kong [États-Unis] ; Emma Kaplan-Lewis [États-Unis] ; Otis W. Brawley [États-Unis] ; Rachel Baden [États-Unis] ; James L. Zazzali [États-Unis] ; Karen S. Miller [États-Unis] ; James Loveless [États-Unis] ; Krutika Jariwala-Parikh [États-Unis] ; Shalini V. Mohan [États-Unis] | Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement. |
| 000065 (2021) |
Guobing Li [République populaire de Chine, États-Unis] ; Shasha Ruan [République populaire de Chine] ; Xiaolu Zhao [République populaire de Chine] ; Qi Liu [États-Unis] ; Yali Dou [États-Unis] ; Fengbiao Mao [République populaire de Chine] | Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. |
| 000077 (2021) |
Muhammad Sani Ismaila [Trinité-et-Tobago] ; Faruku Bande [Nigeria] ; Aminu Ishaka [Nigeria] ; Aminatu Abubakar Sani [Nigeria] ; Karla Georges [Trinité-et-Tobago] | Therapeutic options for COVID-19: a quick review. |
| 000084 (2021) |
Bhanu Prasad Venkatesulu [États-Unis] ; Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Prashanth Giridhar [Inde] ; Pragathee V [Inde] ; Harsh K. Patel [États-Unis] ; Jacob Manteuffel [États-Unis] | The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. |
| 000094 (2021) |
Subham Das [Inde] ; Anu Kunnath Ramachandran [Inde] ; Sumit Raosaheb Birangal [Inde] ; Saleem Akbar [Inde] ; Bahar Ahmed [Inde] ; Alex Joseph [Inde] | The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. |
| 000095 (2021) |
Po-Liang Chen [République populaire de Chine] ; Yi-Han Hsiao [République populaire de Chine] ; Chien Chuang [République populaire de Chine] ; Jia-Yih Feng [République populaire de Chine] ; Hsiang-Ling Ho [République populaire de Chine] ; Yi-Tsung Lin [République populaire de Chine] ; Su-Jung Chen [République populaire de Chine] ; Shiang-Fen Huang [République populaire de Chine] ; Hsin-Pai Chen [République populaire de Chine] ; Teh-Ying Chou [République populaire de Chine] ; Yuh-Min Chen [République populaire de Chine] ; Fu-Der Wang [République populaire de Chine] | The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. |
| 000104 (2021) |
Farah Daou [Liban] ; Gretta Abou-Sleymane [Liban] ; Danielle A. Badro [Liban] ; Nagham Khanafer [France] ; Mansour Tobaiqy [Arabie saoudite] ; Achraf Al Faraj [Liban] | The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. |
| 000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
| 000108 (2021) |
Masashi Ohe [Japon] ; Ken Furuya [Japon] ; Houman Goudarzi [Japon] | Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19? |
| 000114 (2021) |
Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Bhanuprasad Venkatesalu [États-Unis] ; Harsh K. Patel [États-Unis] ; Marco Spadaccini [Italie] ; Jacob Manteuffel [États-Unis] ; Mayur Ramesh [États-Unis] | Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. |
| 000125 (2021) |
Andy Sing Ong Tang ; Tze Shin Leong ; Lee Ping Chew ; Hock Hin Chua | Successful Non-surgical Treatment of an Acute Calculous Cholecystitis in a Myeloma Patient with Covid-19: Case Report. |
| 000130 (2021) |
Yudibeth Sixto-L Pez [Mexique] ; José Correa-Basurto [Mexique] ; Martiniano Bello [Mexique] ; Bruno Landeros-Rivera [France] ; Jose Antonio Garz N-Tiznado [Mexique] ; Sarita Monta O [Mexique] | Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population. |
| 000133 (2021) |
Isidro García-Meni O [Espagne] ; Lorena Forcelledo [Espagne] ; Yaiza Rosete [Espagne] ; Emilio García-Prieto [Espagne] ; Dolores Escudero [Espagne] ; Javier Fernández [Espagne] | Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: The storm after the storm. |
| 000137 (2021) |
Ça La Begüm Apayd N [Turquie] ; Gözde Ç Nar [Turquie] ; Gökçe Cihan-Üstünda [Turquie] | Small-molecule antiviral agents in ongoing clinical trials for COVID-19. |
| 000155 (2021) |
Alberto Enrico Maraolo [Italie] ; Adriano Grossi [Italie] | Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. |
| 000158 (2021) |
Hany M. Dabbous [Égypte] ; Manal H. El-Sayed [Égypte] ; Gihan El Assal [Égypte] ; Hesham Elghazaly [Égypte] ; Fatma F S. Ebeid [Égypte] ; Ahmed F. Sherief [Égypte] ; Maha Elgaafary [Égypte] ; Ehab Fawzy [Égypte] ; Sahar M. Hassany [Égypte] ; Ahmed R. Riad [Égypte] ; Mohamed A. Tageldin [Égypte] | Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. |
| 000160 (2021) |
Saeidreza Jamalimoghadamsiahkali [Iran] ; Besharat Zarezade [Iran] ; Sogol Koolaji [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Abolfazl Zendehdel [Iran] ; Mohammad Tabarestani [Iran] ; Ehsan Sekhavati Moghadam [Iran] ; Ladan Abbasian [Iran] ; Seyed Ali Dehghan Manshadi [Iran] ; Mohamadreza Salehi [Iran] ; Malihe Hasannezhad [Iran] ; Sara Ghaderkhani [Iran] ; Mohsen Meidani [Iran] ; Faeze Salahshour [Iran] ; Fatemeh Jafari [Iran] ; Navid Manafi [Canada] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. |
| 000166 (2021) |
Giulia Fiscon [Italie] ; Federica Conte [Italie] ; Lorenzo Farina [Italie] ; Paola Paci [Italie] | SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. |
| 000169 (2021) |
Bianca D. Balmant [Brésil] ; Raquel S. Torrinhas [Brésil] ; Ilanna M. Rocha [Brésil] ; Danielle C. Fonseca [Brésil] ; Francisco F C. Formiga [Brésil] ; Eloisa S D O. Bonfá [Brésil] ; Eduardo F. Borba [Brésil] ; Dan L. Waitzberg [Brésil] | SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link? |
| 000170 (2021) |
Filipa Silva [Portugal] ; Ana Cipriano [Portugal] ; Hugo Cruz [Portugal] ; Joana Tavares [Portugal] ; Joana Fragoso [Portugal] ; Jorge Malheiro [Portugal] ; Manuela Almeida [Portugal] ; La Salete Martins [Portugal] ; Miguel Abreu [Portugal] ; Sofia Pedroso [Portugal] ; Leonídio Dias [Portugal] ; Ant Nio Castro Henriques [Portugal] | SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases. |
| 000171 (2021) |
Carmen Manciuc [Roumanie] ; Dragos Nemescu [Roumanie] ; Andrei Vata [Roumanie] ; Georgiana Alexandra Lacatusu [Roumanie] | SARS-CoV-2 infection and diabetes mellitus: A North Eastern Romanian experience. |
| 000180 (2021) |
Ilad Alavi Darazam [Iran] ; Shervin Shokouhi [Iran] ; Mohamad Amin Pourhoseingholi [Iran] ; Seyed Sina Naghibi Irvani [Iran] ; Majid Mokhtari [Iran] ; Minoosh Shabani [Iran] ; Mahdi Amirdosara [Iran] ; Parham Torabinavid [Iran] ; Maryam Golmohammadi [Iran] ; Sayedpayam Hashemi [Iran] ; Arsalan Azimi [Iran] ; Mohammad Hossein Jafarazadeh Maivan [Iran] ; Omidvar Rezaei [Iran] ; Alireza Zali [Iran] ; Mohammadreza Hajiesmaeili [Iran] ; Hadiseh Shabanpour Dehbsneh [Iran] ; Akram Hoseyni Kusha [Iran] ; Maryam Taleb Shoushtari [Iran] ; Negar Khalili [Iran] ; Azam Soleymaninia [Iran] ; Latif Gachkar [Iran] ; Ali Khoshkar [Iran] | Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. |
| 000181 (2021) |
Pravindra Kumar [Inde] ; Ashok Kumar Sah [Inde] ; Greesham Tripathi [Inde] ; Anjali Kashyap [Inde] ; Avantika Tripathi [Inde] ; Rashmi Rao [Inde] ; Prabhu C. Mishra [Inde] ; Koustav Mallick [Inde] ; Amjad Husain [Inde] ; Manoj Kumar Kashyap [Inde] | Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. |
| 000185 (2021) |
Sonsoles Salto-Alejandre [Espagne] ; Silvia Jiménez-Jorge [Espagne] ; Nuria Sabé [Espagne] ; Antonio Ramos-Martínez [Espagne] ; Laura Linares [Espagne] ; Maricela Valerio [Espagne] ; Pilar Martín-Dávila [Espagne] ; Mario Fernández-Ruiz [Espagne] ; María Carmen Fari As [Espagne] ; Marino Blanes-Juliá [Espagne] ; Elisa Vidal [Espagne] ; Zaira R. Palacios-Baena [Espagne] ; Román Hernández-Gallego [Espagne] ; Jordi Carratalá [Espagne] ; Jorge Calder N-Parra [Espagne] ; María Ángeles Marcos [Espagne] ; Patricia Mu Oz [Espagne] ; Jesús Fortún-Abete [Espagne] ; José María Aguado [Espagne] ; Francisco Arnaiz-Revillas [Espagne] ; Rosa Blanes-Hernández [Espagne] ; Julián De La Torre-Cisneros [Espagne] ; Luis E. L Pez-Cortés [Espagne] ; Elena García De Vinuesa-Calvo [Espagne] ; Clara M. Rosso [Espagne] ; Jer Nimo Pach N [Espagne] ; Javier Sánchez-Céspedes [Espagne] ; Elisa Cordero [Espagne] | Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. |
| 000190 (2021) |
Dingzhong Li [République populaire de Chine] ; Jianbing Hu [République populaire de Chine] ; Dian Li [République populaire de Chine] ; Weijun Yang [République populaire de Chine] ; Shuang-Feng Yin [République populaire de Chine] ; Renhua Qiu [République populaire de Chine] | Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. |
| 000191 (2021) |
Dhruva Sharma [Inde] ; Neha Sharma [Inde] ; Preksha Sharma [Inde] ; Ganapathy Subramaniam [Inde] | Review of investigational drugs for coronavirus disease 2019. |
| 000195 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000203 (2021) |
F O Shode [Afrique du Sud] ; A S K. Idowu [Afrique du Sud] ; O J Uhomoibhi [Afrique du Sud] ; S. Sabiu [Afrique du Sud] | Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2. |
| 000211 (2021) |
Sebastian E. Sattui [États-Unis] ; Elizabeth R. Graef [États-Unis] ; Jean W. Liew [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Alfred H J. Kim [États-Unis] | Reply to 'Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science'. |
| 000215 (2021) |
Alexandre O. Gérard [France] ; Audrey Laurain [France] ; Audrey Fresse [France] ; Nadège Parassol [France] ; Marine Muzzone [France] ; Fanny Rocher [France] ; Vincent L M. Esnault [France] ; Milou-Daniel Drici [France] | Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000220 (2021) |
Mengmeng Zhao [République populaire de Chine] ; Jishou Zhang [République populaire de Chine] ; Hanli Li [République populaire de Chine] ; Zhen Luo [République populaire de Chine] ; Jing Ye [République populaire de Chine] ; Yao Xu [République populaire de Chine] ; Zhen Wang [République populaire de Chine] ; Di Ye [République populaire de Chine] ; Jianfang Liu [République populaire de Chine] ; Dan Li [République populaire de Chine] ; Menglong Wang [République populaire de Chine] ; Jun Wan [République populaire de Chine] | Recent progress of antiviral therapy for coronavirus disease 2019. |
| 000223 (2021) |
Jessica M. Franklin [États-Unis] ; Kueiyu Joshua Lin [États-Unis] ; Nicolle M. Gatto [États-Unis] ; Jeremy A. Rassen [États-Unis] ; Robert J. Glynn [États-Unis] ; Sebastian Schneeweiss [États-Unis] | Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. |
| 000227 (2021) |
Iwein Gyselinck [Belgique] ; Wim Janssens [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] | Rationale for azithromycin in COVID-19: an overview of existing evidence. |
| 000249 (2021) |
Bianza Moise Bakadia ; Feng He [République populaire de Chine] ; Tiatou Souho [Togo] ; Lallepak Lamboni [Togo] ; Muhammad Wajid Ullah [République populaire de Chine] ; Biaou Ode Boni [République populaire de Chine] ; Abeer Ahmed Qaed Ahmed [République populaire de Chine] ; Biampata Mutu Mukole ; Guang Yang [République populaire de Chine] | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. |
| 000269 (2021) |
Miguel Angel Martinez [Espagne] | Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. |
